Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 30;22(4):656-660.
doi: 10.5056/jnm16035.

A New Approach to the Prophylaxis of Cyclic Vomiting: Topiramate

Oya B Sezer  1 , Taner Sezer  2
Affiliations

A New Approach to the Prophylaxis of Cyclic Vomiting: Topiramate

Oya B Sezer et al. J Neurogastroenterol Motil. .

Erratum in

  • Erratum.
    Sezer OB, Sezer T. Sezer OB, et al. J Neurogastroenterol Motil. 2019 Jan 31;25(1):174. doi: 10.5056/jnm25012. J Neurogastroenterol Motil. 2019. PMID: 30646490 Free PMC article.

Abstract

Background/aims: The aim of this study was to compare the efficacy and tolerability of topiramate and propranolol in preventing pediatric cyclic vomiting syndrome.

Methods: A retrospective medical-record review of patients who underwent prophylaxis after receiving a diagnosis of cyclic vomiting syndrome was performed. Patients who completed at least 12 months of treatment were included in the analysis. Responder rate, and adverseevent rates were also calculated from all patients. Response to treatment was assessed as the total number of vomiting attacks per year. Patients in whom the frequency of vomiting attack reduced greater or equal to 50% were defined as responders, and the remaining patients were classified as nonresponders.

Results: A total of 38 patients who were treated prophylactically with either topiramate (16 patients) or propranolol (22 patients) were identified. Fifty-nine percent of the patients in the propranolol group and 81% of the patients in the topiramate group reported freedom from attacks. A decrease of more than 50% in attacks per year occurred in 23% of patients in the propranolol group and 13% of patients in the topiramate group. The responder rates were 81% for propranolol group and 94% for topiramate group (P = 0.001). Despite minor adverse effects (drowsiness, nervousness, and dizziness) observed in a few patients, the adverse event rates were not significantly different between the 2 groups (P = 0.240).

Conclusions: The efficacy of topiramate was superior to propranolol for the prophylaxis of pediatric cyclic vomiting syndrome.

Keywords: Cyclic vomiting syndrome; Propranolol; Topiramate.

PubMed Disclaimer

Figures

Figure
Figure
Diagram showing the distribution and outcomes after the prophylactic treatment for cyclic vomiting syndrome.
See this image and copyright information in PMC

References

    1. Abell TL, Adams KA, Boles RG, et al. Cyclic vomiting syndrome in adults. Neurogastroenterol Motil. 2008;20:269–284. doi: 10.1111/j.1365-2982.2008.01113.x. - DOI - PubMed
    1. Yang HR. Recent concepts on cyclic vomiting syndrome in children. J Neurogastroenterol Motil. 2010;16:139–147. doi: 10.5056/jnm.2010.16.2.139. - DOI - PMC - PubMed
    1. Ertekin V, Selimoglu MA, Altnkaynak S. Prevalence of cyclic vomiting syndrome in a sample of Turkish school children in an urban area. J Clin Gastroenterol. 2006;40:896–898. doi: 10.1097/01.mcg.0000212627.83746.0b. - DOI - PubMed
    1. Fitzpatrick E, Bourke B, Drumm B, Rowland M. The incidence of cyclic vomiting syndrome in children: population-based study. Am J Gastroenterol. 2008;103:991–995. doi: 10.1111/j.1572-0241.2007.01668.x. - DOI - PubMed
    1. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377–1390. doi: 10.1053/j.gastro.2006.03.008. - DOI - PubMed

LinkOut - more resources